Here we can show for the first time that the efficacy of PMD-026 and RSK inhibition in general extends to malignant melanoma cells with MAPK pathway hyperactivation, including not only the BRAFMut subgroup irrespective of the response to MAPK pathway inhibitors but also melanomas with RASMut or NF-1LOF, for which no effective targeted treatment options have been yet available. This evidence concerns the gene RPS6KA3 and melanoma.